R. Hrin

发表

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Michael D. Miller, W. Schleif, R. Geleziunas, 2005, Proceedings of the National Academy of Sciences of the United States of America.

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions

J. Shiver, J. Joyce, M. Chastain, 2008, Proceedings of the National Academy of Sciences.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp 41 epitope

D. Hazuda, R. Cortese, G. Ciliberto, 2005 .

Acetylcholinesterase expression in NTera 2 human neuronal cells: A model for developmental expression in the nervous system

D. Kolson, R. Collman, R. Hrin, 1995, Journal of neuroscience research.

Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41.

J. Condra, A. Pessi, J. Joyce, 2008, AIDS research and human retroviruses.

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Joseph Kessler, Anthony Carella, D. Hazuda, 2005, Bioorganic & medicinal chemistry letters.

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

John P. Moore, T. Ketas, F. Bonelli, 2009, Proceedings of the National Academy of Sciences.

Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold.

D. Hazuda, S. Venkatraman, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 5R- and 5S-methyl substituted D- and L-configuration 1,3-dioxolane nucleoside analogs.

W. Schleif, J. Tomassini, M. Maccoss, 2004, Bioorganic & Medicinal Chemistry.

Assessment of the susceptibility of mutant HIV-1 to antiviral agents.

D. Hazuda, C. Coburn, Kristen L G Jones, 2010, Journal of virological methods.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Gennaro Ciliberto, Peter S Kim, Simon Lennard, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Small Molecule Mimetics of an HIV-1 gp41 Fusion Intermediate as Vaccine Leads

G. McGaughey, E. Ottinger, M. Citron, 2010, The Journal of Biological Chemistry.

Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.

Laughlin, C. Debouck, D. Kolson, 1994, The Journal of general virology.

Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.

C. Debouck, D. Kolson, J. W. Balliet, 1994, The Journal of general virology.

Distinct Mutation Pathways of Non-Subtype B HIV-1 during In Vitro Resistance Selection with Nonnucleoside Reverse Transcriptase Inhibitors

D. Hazuda, G. McGaughey, Youwei Yan, 2010, Antimicrobial Agents and Chemotherapy.

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates

D. Montefiori, J. Shiver, A. Finnefrock, 2010, Proceedings of the National Academy of Sciences.

Antiviral Activity and In Vitro Mutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase Inhibitor

D. Hazuda, G. McGaughey, Youwei Yan, 2012, Antimicrobial Agents and Chemotherapy.

Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays.

W. Strohl, D. Montgomery, Barrett R Harvey, 2007, Journal of immunological methods.

Structural basis for HIV-1 neutralization by a gp41 fusion intermediate–directed antibody

M. Luftig, R. Geleziunas, A. Carfi, 2006, Nature Structural &Molecular Biology.

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41

J. Condra, A. Finnefrock, M. Luftig, 2009, mAbs.